Johnson & Johnson to Pay $2B to Settle False Marketing Cases

It promoted a drug beyond its approved uses

   

johnson & johnson corporate 630On Monday, the U.S. Department of Justice said that it had reached a settlement agreement with Johnson & Johnson (JNJregarding the improper marketing an antipsychotic drug.

The company will pay $2.2 billion to settle civil and criminal claims over the way it promoted Risperdal. The deal includes $485 million in criminal fines and $1.74 billion in civil penalties, USA TODAY notes.

Johnson and Johnson Recalls Infant Motrin Over Plastic Particles
Johnson and Johnson Recalls Infant Motrin Over Plastic Particles

Federal regulators granted approval for Risperdal to be given to patients suffering schizophrenia. However, a Johnson & Johnson subsidiary promoted the drug for a much broader range of issues in peoples suffering from age-related dementia.

The government said that sales representatives were compensated for marketing the drug beyond its approved application. The subsidiary that marketed the drug for off-label purposes was hit with criminal charges, including misbranding and making “false and misleading statements” about the drug.

Claims regarding two other drugs — Invega and Natrecor — are also covered by the civil settlement.

Shares of Johnson & Johnson fell modestly in Tuesday morning trading.


Article printed from InvestorPlace Media, http://investorplace.com/2013/11/johnson-johnson-pay-2b-settle-false-marketing-cases/.

©2016 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.